Dublin, Oct. 13, 2016 -- Research and Markets has announced the addition of the "Stem Cell Assay Market by Type (Viability, Differentiation, Cell Identification), Kit (Mesenchymal, IPSCS, Hematopoietic), Product (Flow Cytometer, Detection Kit), Application (Regenerative Medicines, Drug Development), End User - Forecast to 2021" report to their offering.
The global stem cell assay market is expected to reach USD 1,363.3 million by 2021 from USD 536.6 million in 2016, at a CAGR of 20.5% from 2016 to 2021.
Factors such as high prevalence of chronic diseases, increasing investment in research related activities, and technological advancements are driving the growth in the global stem cell assay market. However, stringent regulatory policies and the high cost of stem cell based therapies are the major factors restraining the growth of this market.
The global stem cell assay market has been segmented on the basis of type of assay, kit, detection, instrument, application, end-user, and region. The viability/cytotoxicity segment is expected to account for the largest and fastest-growing segment of the global stem cell assay market in 2016. The increasing focus of the pharmaceutical industries on drug screening has resulted in the increase in demand for stem cell assays.
The major players in the global stem cell assay market include
- Bio Rad
- Cell Bio Labs, Inc.
- Cellular Dynamics International.
- GE Healthcare
- Hemogenix Inc.
- Merck Millipore
- Promega Corporation
- R&D Systems
- Stem Cell Technologies
- Thermo Fisher Scientific Pvt. Ltd
Key Topics Covered:
1 Introduction
2 Research Methodology
3 Executive Summary
4 Premium Insights
5 Market Overview
6 Stem Cell Assay Market, By Technology
7 Stem Cell Assay Market, By Assay
8 Stem Cell Assay Market, By Kits
9 Stem Cell Assay Market, By Product
10 Stem Cell Assays Market, By Application
11 Stem Cell Assays, By End User
12 Regional Analysis
13 Competitive Landscape
14 Company Profiles
For more information about this report visit http://www.researchandmarkets.com/research/mj7nn6/stem_cell_assay
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Stem Cells


Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 



